Medivation Announces Change in Executive Management Team

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Medivation Announces Change in Executive Management Team

SAN FRANCISCO, CA--(Marketwired - Jul 10, 2014) - Medivation, Inc. ( NASDAQ : MDVN ) today announced Dawn Svoronos (formerly Graham) has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, chief executive officer and president of Medivation. Ms. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. Inc, where she oversaw commercial operations in approximately 30 EU and EU accession countries. Ms. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the Company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the Company to pursue other opportunities.

"We thank Cheryl for her years of service to Medivation and wish her the best," said David Hung, M.D., president and chief executive officer of Medivation, Inc. "We are fortunate to have Dawn Svoronos, a seasoned executive with significant commercial expertise, step in on an interim basis to lead Medivation's commercial operations."

Ms. Svoronos, who was elected to Medivation's Board of Directors in April 2013, has more than 30 years of pharmaceutical industry experience spanning the U.S., Europe, Asia and Canada. In March 2011, Ms. Svoronos retired from Merck & Co., Inc, one of the world's leading healthcare companies, where she worked in the commercial side of the organization for 23 years. Ms. Svoronos is a former President of Europe and Canada for Merck. Before moving to Europe, Ms. Svoronos was President of Merck in Canada and prior to that, she was Vice President of Merck for Asia Pacific where she focused on advancing the commercial interests of Merck in Japan, China, and several other countries in Southeast Asia.

Medivation currently markets XTANDI ® (enzalutamide) capsules with its collaboration partner Astellas Pharma, Inc. XTANDI is currently approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel chemotherapy. In March 2014, Astellas and Medivation submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval of XTANDI for the treatment of men with metastatic prostate cancer that has progressed on LHRH therapy or after bilateral orchiectomy. In May 2014, the FDA granted the sNDA application Priority Review designation with a Prescription Drug User Fee Act date of September 18, 2014.

Important Safety Information for XTANDI (from the approved prescribing information) Contraindications: XTANDI can cause fetal harm when administered to a pregnant woman based on its mechanism of action. XTANDI is not indicated for use in women. XTANDI is contraindicated in women who are or may become pregnant.

Warnings and Precautions: In the randomized clinical trial, seizure occurred in 0.9% of patients on XTANDI. No patients on the placebo arm experienced seizure. Patients experiencing a seizure were permanently discontinued from therapy. All seizures resolved. Patients with a history of seizure, taking medications known to decrease the seizure threshold, or with other risk factors for seizure were excluded from the clinical trial. Because of the risk of seizure associated with XTANDI use, patients should be advised of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.

Adverse Reactions: The most common adverse drug reactions ( ≥ 5%) reported in patients receiving XTANDI in the randomized clinical trial were asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade 1-4 neutropenia occurred in 15% of XTANDI patients (1% Grade 3-4) and in 6% on placebo (no Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of XTANDI patients and 2% on placebo. One percent of XTANDI patients compared to 0.3% on placebo died from infections or sepsis. Falls or injuries related to falls occurred in 4.6% of XTANDI patients versus 1.3% on placebo. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in XTANDI patients and included non-pathologic fractures, joint injuries, and hematomas. Grade 1 or 2 hallucinations occurred in 1.6% of XTANDI patients and 0.3% on placebo, with the majority on opioid-containing medications at the time of the event.

Drug Interactions - Effect of Other Drugs on XTANDI: Administration of strong CYP2C8 inhibitors can increase the plasma exposure to XTANDI. Co-administration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible. If co-administration of XTANDI cannot be avoided, reduce the dose of XTANDI. Co-administration of XTANDI with strong or moderate CYP3A4 and CYP2C8 inducers can alter the plasma exposure of XTANDI and should be avoided if possible.

Effect of XTANDI on Other Drugs: XTANDI is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans. Avoid CYP3A4, CYP2C9 and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.

For Full Prescribing Information for XTANDI (enzalutamide) capsules, please visit www.XtandiHCP.com .

About Medivation Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com .

Contacts: Rick Bierly Chief Financial Officer (415) 543-3470 Anne Bowdidge Sr. Director, Investor Relations (650) 218-6900

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 134

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 174

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 56

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 132

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 82

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 108

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 118

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 98

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Gold's Surge Amid Global Trade Uncertainties

Updated Category News Views 169

Gold Prices Soar Amid Trade Tensions Gold prices have seen a significant uptick recently as trade tariffs and a softer US dollar create a favorable environment for this precious metal. The price of gold rose by 1.23%, which is largely attributed to a weakened dollar and increasing demand for safe-haven assets. As international markets react to geopolitical uncertainties,...

Continue Reading
La Compagnie Unveils NYC-Düsseldorf Flight Plans

Updated Category News Views 47

A new chapter is unfolding in the skies over the Atlantic. La Compagnie is gearing up to connect New York to Düsseldorf with a direct, all-business-class flight starting in Spring 2027. This move is ambitious, tapping into the bustling economic energy present across the North Rhine-Westphalia region—an economic powerhouse littered with U.S.-affiliated businesses. A...

Continue Reading
Hydro One Announces Upcoming Financial Results Teleconference

Updated Category News Views 251

Hydro One Plans to Release First Quarter Financial Results On May 8, 2025, Hydro One Limited (TSX: H), Ontario's largest electric transmission and distribution utility, will unveil its first quarter financial results before North American markets open. This timely announcement marks an important moment for investors as they look to assess the company’s performance....

Continue Reading
HiBob Introduces Innovative HR Solutions for Small Businesses

Updated Category News Views 515

HiBob Launches Innovative SMB HR Solutions HiBob, the creator of the award-winning HR platform Bob, has recently introduced a specialized solution tailored for small to medium-sized businesses in the UK, particularly those with 50 to 200 employees. This new offering aims to simplify people management, providing transparent packages that address the essential needs of...

Continue Reading
The Remarkable Rise of AutoZone: A 20-Year Investment Story

Updated Category News Views 237

Understanding AutoZone's Market Performance AutoZone (NYSE: AZO) has shown remarkable growth over the past two decades, consistently beating the market with an impressive average annual return of 20.73%. This performance translates to a significant compounded return, demonstrating the power of long-term investing. The Impact of Compounding Returns Consider this scenario:...

Continue Reading